This Article Full Text Full Text (PDF) Other Versions of this Article: AAC.00202-07v1 51/6/2223    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pillai, S. K. Articles by Eliopoulos, G. M. Search for Related Content PubMed PubMed Citation Articles by Pillai, S. K. Articles by Eliopoulos, G. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2007, p. 2223-2225, Vol. 51, No. 6
0066-4804/07/$08.00+0     doi:10.1128/AAC.00202-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Daptomycin Nonsusceptibility in Staphylococcus aureus with Reduced Vancomycin Susceptibility Is Independent of Alterations in MprF

Department of Infectious Disease, Cleveland Clinic Foundation, Cleveland, Ohio,¹ Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts,² Harvard Medical School, Boston, Massachusetts,³ Department of Medicine and Division of Infectious Diseases, New York Medical College and Westchester Medical Center, Valhalla, New York 10595⁴

Received 11 February 2007/ Returned for modification 12 March 2007/ Accepted 21 March 2007

A previous study documented the presence of mutations in mprF that accompanied the loss of daptomycin susceptibility among Staphylococcus aureus isolates following exposure to the drug. An association between the development of glycopeptide-intermediate S. aureus and daptomycin nonsusceptibility has also been recently described. We report that among three clinical S. aureus isolates which developed vancomycin heteroresistance, as well as daptomycin nonsusceptibility despite a lack of exposure to this drug, there were no mutations resulting in amino acid substitutions in MprF.

Published ahead of print on 2 April 2007.

This article has been cited by other articles:

• Warren, R. E. (2008). Daptomycin in endocarditis and bacteraemia: a British perspective. J Antimicrob Chemother 62: iii25-iii33 [Abstract] [Full Text]  
• Rose, W. E., Leonard, S. N., Sakoulas, G., Kaatz, G. W., Zervos, M. J., Sheth, A., Carpenter, C. F., Rybak, M. J. (2008). Daptomycin Activity against Staphylococcus aureus following Vancomycin Exposure in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations. Antimicrob. Agents Chemother. 52: 831-836 [Abstract] [Full Text]  
• Montero, C. I., Stock, F., Murray, P. R. (2008). Mechanisms of Resistance to Daptomycin in Enterococcus faecium. Antimicrob. Agents Chemother. 52: 1167-1170 [Abstract] [Full Text]  
• Jones, T., Yeaman, M. R., Sakoulas, G., Yang, S.-J., Proctor, R. A., Sahl, H.-G., Schrenzel, J., Xiong, Y. Q., Bayer, A. S. (2008). Failures in Clinical Treatment of Staphylococcus aureus Infection with Daptomycin Are Associated with Alterations in Surface Charge, Membrane Phospholipid Asymmetry, and Drug Binding. Antimicrob. Agents Chemother. 52: 269-278 [Abstract] [Full Text]  
• Julian, K., Kosowska-Shick, K., Whitener, C., Roos, M., Labischinski, H., Rubio, A., Parent, L., Ednie, L., Koeth, L., Bogdanovich, T., Appelbaum, P. C. (2007). Characterization of a Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus Strain in a Patient with Endocarditis. Antimicrob. Agents Chemother. 51: 3445-3448 [Abstract] [Full Text]